Publication:
AADAC promotes therapeutic activity of cisplatin and imatinib against ovarian cancer cells

Simple item page
dc.contributor.authorWang, Haijing
dc.contributor.authorWang, Disong
dc.contributor.authorGu, Tingting
dc.contributor.authorZhu, Mengjiao
dc.contributor.authorCheng, Ling
dc.contributor.authorDa, Wentao
dc.date.accessioned2023-03-01T09:50:37Z
dc.date.available2023-03-01T09:50:37Z
dc.date.issued2022
dc.description.abstractObjective. To explore how AADAC functions in the malignant progression of ovarian cancer, and the effect of AADAC on drug therapeutic activity against ovarian cancer cells. Methods. AADAC level in tumor and normal samples from TCGA-OV dataset and its survival significance were analyzed by bioinformatics methods. Signaling pathway enrichment analysis for the high- and low-AADAC patients was achieved by using GSEA software. AADAC expression in the cell lines with different treatments was evaluated via qRT-PCR. Cell proliferative ability was assessed via MTT assay Cell migratory and invasive abilities were evaluated via transwell assay. Angiogenesis assay was performed to examine the angiogenetic ability. Results. AADAC was upregulated in ovarian cancer tissues, and patients with high expression of AADAC had favorable survival conditions compared to the low AADAC expression ones. Overexpression of AADAC inhibited the malignant progression of ovarian cancer cells. Both cisplatin and imatinib suppressed cancer cell malignant progression, while overexpressed AADAC synergistically enhanced such inhibition. Conclusions. The study demonstrated that AADAC could somehow suppress the malignant progression of ovarian cancer, especially at the cellular level. In addition, synergic tumor-inhibitory effects between AADAC and the anti-cancer drugs were identified. All the above results proposed a novel idea and candidate biomarker for ovarian cancer therapy.es
dc.formatapplication/pdfes
dc.format.extent9es
dc.identifier.citationHistology and Histopathology Vol. 37, nº9 (2022)
dc.identifier.doihttps://doi.org/ 10.14670/HH-18-460
dc.identifier.issn0213-3911
dc.identifier.issn1699-5848
dc.identifier.urihttp://hdl.handle.net/10201/128928
dc.languageenges
dc.publisherUniversidad de Murcia, Departamento de Biologia Celular e Histiologiaes
dc.relationSin financiación externa a la Universidades
dc.rightsinfo:eu-repo/semantics/openAccesses
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectAADACes
dc.subjectOvarian canceres
dc.subjectCisplatines
dc.subjectImatinibes
dc.subjectMalignant progressiones
dc.subject.otherCDU::6 - Ciencias aplicadas::61 - Medicina::616 - Patología. Medicina clínica. Oncologíaes
dc.titleAADAC promotes therapeutic activity of cisplatin and imatinib against ovarian cancer cellses
dc.typeinfo:eu-repo/semantics/articlees
dspace.entity.typePublicationes
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Wang-37-899-907-2022.pdf
Size:
4.14 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.39 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Histology and histopathology Vol.37, nº9 (2022)